Hypnotics' association with mortality or cancer: A matched cohort study

BMJ Open

Volumn 2, Issue 1, 2012, Pages

  Kripke, Daniel F ^a   Langer, Robert D ^b   Kline, Lawrence E ^a  

^a SCRIPPS CLINIC   (United States)

^b Jackson Hole Center for Preventive Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; ESZOPICLONE; HYPNOTIC AGENT; TEMAZEPAM; ZALEPLON; ZOLPIDEM;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; PROPORTIONAL HAZARDS MODEL; UNITED STATES;

EID: 84859092587     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-000850     Document Type: Article

References (41)

1. International Narcotics Control Board. Psychotropic Substances: Statistics for 2008; Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971. New York: United Nations, 2010.
2. Petersen A. Dawn of a new sleep drug? Wall St J 2011:D1-4.
3. Hammond EC. Smoking in relation to the death rates of one million men and women. Natl Cancer Inst Monogr 1966;19:127-204.
4. Kripke DF, Simons RN, Garfinkel L, et al. Short and long sleep and sleeping pills: is increased mortality associated? Arch Gen Psychiatry 1979;36:103-16. (Pubitemid 10187555)
5. Merlo J, Hedblad B, Ogren M, et al. Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics-hypnotics and analgesics. Eur J Clin Pharmacol 1996;49:261-5.
6. Kripke DF, Klauber MR, Wingard DL, et al. Mortality hazard associated with prescription hypnotics. Biol Psychiatry 1998;43:687-93. (Pubitemid 28222390)
7. Mallon L, Broman JE, Hetta J. Is usage of hypnotics associated with mortality? Sleep Med 2009;10:279-86.
8. Belleville G. Mortality hazard associated with anxiolytic and hypnotic drug use in the national population health survey. Can J Psychiatry 2010;55:137-46.
9. McCall WV, Fleischer AB Jr, Feldman SR. Diagnostic codes associated with hypnotic medications during outpatient physicianpatient encounters in the United States from 1990-1998. Sleep 2002;25:221-3. (Pubitemid 34193584)
10. Zosel A, Osterberg EC, Mycyk MB. Zolpidem misuse with other medications or alcohol frequently results in intensive care unit admission. Am J Ther 2011;18:305-8.
11. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009;47:911-1084.
12. Kripke DF. Greater incidence of depression with hypnotics than with placebo. BMC Psychiatry 2007;7:42.
13. Allgulander C, Ljungberg L, Fisher LD. Long-term prognosis in addiction on sedative and hypnotic drugs analyzed with the Cox regression model. Acta Psychiatr Scand 1987;75:521-31. (Pubitemid 17119457)
14. Carlsten A, Waern M. Are sedatives and hypnotics associated with increased suicide risk in the elderly? BMC Geriatr 2009;9:20.
15. Rod NH, Vahtera J, Westerlund H, et al. Sleep disturbances and cause-specific mortality: results from the GAZEL cohort study. Am J Epidemiol 2010;173:300-9.
16. Mallon L, Broman JE, Hetta J. Relationship between insomnia, depression, and mortality: a 12-year follow-up of older adults in the community. Int Psychogeriatr 2000;12:295-306.
17. Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord 2002;72:227-36. (Pubitemid 35351282)
18. Vermeeren A, Coenen AM. Effects of the use of hypnotics on cognition. Prog Brain Res 2011;190:89-103.
19. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701-7. (Pubitemid 19019577)
20. Wang PS, Bohn RL, Glynn RJ, et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001;49:1685-90. (Pubitemid 34007997)
21. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169.
22. Gustavsen I, Bramness JG, Skurtveit S, et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008;9:18-22.
23. Cirignotta F, Mondini S, Zucconi M, et al. Zolpidempolysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome. Pharmacol Biochem Behav 1988;29:807-9. (Pubitemid 19260932)
24. Guilleminault C. Benzodiazepines, breathing, and sleep. Am J Med 1990;88:25Se8.
25. Eckert DJ, Owens RL, Kehlmann GB, et al. Eszopiclone increases the respiratory arousal threshold and lowers the apnea/hypopnea index in obstructive sleep apnea patients with low arousal threshold. Clin Sci (Lond) 2011;120:505-14.
26. Jean-Louis G, Brown CD, Zizi F, et al. Cardiovascular disease risk reduction with sleep apnea treatment. Expert Rev Cardiovasc Ther 2010;8:995-1005.
27. Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002;3:323-7.
28. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs 2008;22:1021-36.
29. Tsai JH, Yang P, Chen CC, et al. Zolpidem-induced amnesia and somnambulism: rare occurrences? Eur Neuropsychopharmacol 2009;19:74-6.
30. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007;22:1335-50. (Pubitemid 47247294)
31. Gagliardi GS, Shah AP, Goldstein M, et al. Effect of zolpidem on the sleep arousal response to nocturnal esophageal acid exposure. Clin Gastroenterol Hepatol 2009;7:948-52.
32. Joya FL, Kripke DF, Loving RT, et al. Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med 2009;5:377-83.
33. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
34. Kripke DF. Possibility that certain hypnotics might cause cancer in skin. J Sleep Res 2008;7:245-50.
35. Althuis MD, Fredman L, Langenberg PW, et al. The relationship between insomnia and mortality among community-dwelling older women. J Am Geriatr Soc 1998;46:1270-3. (Pubitemid 28467431)
36. Kripke DF, Garfinkel L, Wingard DL, et al. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002;59:131-6. (Pubitemid 34137380)
37. Phillips B, Mannino DM. Does insomnia kill? Sleep 2005;28:965-71. (Pubitemid 41170931)
38. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003;327:1459-61. (Pubitemid 38045824)
39. National Institute for Clinical Excellence. Guidance of the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. Technol Appraisal 2004;77:1-27.
40. Jacobs GD, Pace-Schott EF, Stickgold R, et al. Cognitive behavior therapy and pharmacotherapy for insomnia. Arch Intern Med 2004;164:1888-96.
41. Kyle SD, Morgan K, Spiegelhalder K, et al. No pain, no gain: an exploratory within-subjects mixed-methods evaluation of the patient experience of sleep restriction therapy (SRT) for insomnia. Sleep Med 2011;12:735-47.